Efficacy and safety of tacrolimus ointment 0·1% vs. betamethasone 17-valerate 0·1% in the treatment of chronic paronychia: An unblinded randomized study

British Journal of Dermatology

Volumn 163, Issue 1, 2010, Pages 208-

  Rao, A ^a   Bunker, C ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

betamethasone 17 valerate; chronic paronychia; placebo; tacrolimus

Indexed keywords

BETAMETHASONE VALERATE; EMOLLIENT AGENT; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; LETTER; PARONYCHIA; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT RESPONSE; HUMAN; NOTE; OINTMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BETAMETHASONE 17-VALERATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; PARONYCHIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS;

EID: 77953980509     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09784.x     Document Type: Letter

References (1)

1. Rigopoulos D, Gregoriou S, Belyayeva E et al. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 2009 160 : 858 860.